Thus, intratumoral CXCL13+ T cells are indicative of existing anti-tumour immunity and predictive of a positive response to immunotherapy which, in addition to direct tumour cell killing, may derive from their potential to facilitate TLS formation and B cell recruitment. The gene discussed is CXCL13; the disease is neoplasm.